SEARCH

SEARCH BY CITATION

References

  • Bern C, Adler-Moore J, Berenguer J et al. (2006) Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clinical Infectious Diseases 43, 917924.
  • Bryceson A (2001) A policy for leishmaniasis with respect to the prevention and control of drug resistance. Tropical Medicine and International Health 6, 928934.
  • Chappuis F, Mueller Y, Nguimfack A et al. (2005) Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. Journal of Clinical Microbiology 43, 59735977.
  • Collin S, Davidson R, Ritmeijer K et al. (2004) Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clinical Infectious Diseases 38, 612619.
  • Croft SL, Sundar S & Fairlamb AH (2006) Drug resistance in leishmaniasis. Clinical Microbiology Reviews 19, 111126.
  • Delgado J, Macias J, Pineda JA et al. (1999) High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. American Journal of Tropical Medicine and Hygiene 61, 766769.
  • Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comparative Immunology, Microbiology and Infectious Diseases 27, 305318.
  • Guerin PJ, Olliaro P, Sundar S et al. (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infectious Diseases 2, 494501.
  • Jamjoom MB, Ashford RW, Bates PA et al. (2004) Leishmania donovani is the only cause of visceral leishmaniasis in East Africa; previous descriptions of L. infantum and “L. archibaldi” from this region are a consequence of convergent evolution in the isoenzyme data. Parasitology 129, 399409.
  • Lyons S, Veeken H & Long J (2003) Visceral leishmaniasis and HIV in Tigray, Ethiopia. Tropical Medicine and International Health 8, 733739.
  • Moore E, O’Flaherty D, Heuvelmans H et al. (2001) Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bulletin of the World Health Organization 79, 388393.
  • Mueller M, Balasegaram M, Koummuki Y et al. (2006) A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. Journal of Antimicrobial Chemotherapy 58, 811815.
  • Mueller Y, Nguimfack A, Cavailler P et al. (2008) Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Annals of Tropical Medicine and Parasitology 102, 1119.
  • Olliaro PL, Guerin PJ, Gerstl S et al. (2005) Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infectious Diseases 5, 763774.
  • Ritmeijer K, Veeken H, Melaku Y et al. (2001) Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Transactions of the Royal Society of Tropical Medicine and Hygiene 95, 668672.
  • Ritmeijer K, Dejenie A, Assefa Y et al. (2006) A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clinical Infectious Diseases 43, 357364.
  • Seaman J, Mercer AJ, Sondorp HE & Herwaldt BL (1996) Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Annals of Internal Medicine 124, 664672.
  • Sundar S, Mehta H, Suresh AV et al. (2004) Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clinical Infectious Diseases 38, 377383.
  • Thakur CP & Ahmed S (2001) Observations on amphotericin B treatment of kala-azar given in a rural set up in Bihar, India. Indian Journal of Medical Research 113, 1418.
  • Veeken H, Ritmeijer K, Seaman J & Davidson R (2000) A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Tropical Medicine and International Health 5, 312317.
  • WHO (1996) Visceral leishmaniasis control. WHO, Geneva.